scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.VACCINE.2016.06.058 |
P698 | PubMed publication ID | 27373596 |
P2093 | author name string | Qin Yan | |
Yali Qin | |||
Zishu Pan | |||
Longyun Chen | |||
Mingzhou Chen | |||
Linjuan Wu | |||
P2860 | cites work | Evaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine Vehicle | Q27473287 |
Ligation-independent cloning of PCR products (LIC-PCR) | Q29618962 | ||
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. | Q30370147 | ||
Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines | Q33657931 | ||
Expression, purification and characterization of enterovirus-71 virus-like particles | Q33788579 | ||
Neurologic complications in children with enterovirus 71 infection | Q33875092 | ||
Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. | Q33908518 | ||
Clinical features, diagnosis, and management of enterovirus 71. | Q34144978 | ||
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents | Q34273164 | ||
Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses | Q34459935 | ||
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses | Q34598925 | ||
An overview of the evolution of enterovirus 71 and its clinical and public health significance | Q34635602 | ||
Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha | Q34717937 | ||
Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus | Q34742846 | ||
Biophysical studies of vesicular stomatitis virus | Q35144870 | ||
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. | Q35635393 | ||
Vesicular stomatitis virus: re-inventing the bullet | Q35761892 | ||
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus | Q36239796 | ||
Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice | Q36423935 | ||
Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein | Q36672543 | ||
In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation | Q37354600 | ||
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy | Q37418123 | ||
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. | Q37714030 | ||
Virology, epidemiology, pathogenesis, and control of enterovirus 71. | Q37801742 | ||
Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression | Q39233488 | ||
Survey of enterovirus infections from hand, foot and mouth disease outbreak in China, 2009. | Q39495121 | ||
Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology | Q39753151 | ||
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial | Q40144208 | ||
The role of TH1 and TH2 subsets in human infectious diseases | Q40742872 | ||
Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope | Q40898990 | ||
Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. | Q44201038 | ||
Immunogenicity of a truncated enterovirus 71 VP1 protein fused to a Newcastle disease virus nucleocapsid protein fragment in mice. | Q45362744 | ||
Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge | Q45396589 | ||
Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus | Q45734536 | ||
Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. | Q47736273 | ||
Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71 | Q95821973 | ||
P433 | issue | 35 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | vesicular stomatitis | Q11549084 |
P304 | page(s) | 4196-4204 | |
P577 | publication date | 2016-06-30 | |
P1433 | published in | Vaccine | Q7907941 |
P1476 | title | Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges | |
P478 | volume | 34 |
Q88883557 | Antivirals and vaccines for Enterovirus A71 |
Q45324939 | Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice |
Q54247724 | Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71. |
Q47553138 | Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo. |
Q92335586 | Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens |
Search more.